OncoDEEP -Biomarker Tests Kits
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn`t work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint the therapeutic vulnerabilities of a tumor and identify appropriate cancer treatment options in a fast turnaround.
- At diagnosis
- First-line treatment not efficient
- Recurrence of cancer
- Highly aggressive or rare cancers
- Primary origin of cancer unknown
OncoDEEP® is the most comprehensive biomarker test available on the market. It covers a wide range of cancer biomarkers carefully selected for their clinical relevance and offers a unique combination of analyses (NGS test and IHC test) that proved to maximize the clinical benefits for cancer patients.
In one simple biomarker test and in less than two weeks, OncoDEEP® can help you to:
- Identify all the approved cancer treatments likely to be effective for your patients;
- Define which types of cancer therapies your patient is resistant to;
- Consider appropriate oncology clinical trials;
- Understand why a cancer treatment stopped working.
- Stage 3-4 solid tumors in adults
- Glioblastoma in children
- Cancer of unknown primary
DISCOVER THE MOLECULAR PROFILE OF A TUMOR
Thanks to biomarker testing, it is now possible to examine the therapeutic vulnerabilities of an individual tumor. Running one single comprehensive biomarker test is often cheaper and faster than deploying multiple genomic cancer tests on small NGS cancer panel. It is also less likely to exhaust a tumor tissue biopsy. OncoDEEP® uniquely combines IHC testing and NGS testing, targeting a large cancer panel of over 600 genes and cancer-specific biomarkers. It screens for cancer gene mutations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapy, immunotherapy, hormonal therapy and chemotherapy.
OBTAIN PATIENT-SPECIFIC CLINICAL RECOMMENDATIONS
OncoDEEP® biomarker test comes with a clinical interpretation of the complex genomic and molecular data. The interpretation is supported by OncoDNA’s proprietary curated database that matches your patient’s tumor profile with relevant cancer treatment options. Our database is kept up to date with all the latest developments in cancer treatment. The final report will be made available in less than two weeks on OncoSHARE, our secure clinical decision support software. On OncoSHARE, you will be able to visualize your patient report, download it in PDF format, and discuss your patient case with other healthcare professionals through virtual meetings and tumor boards.
BENEFIT FROM AN INDIVIDUAL SUPPORT EVERY STEP OF THE WAY
From the biomarker test evaluation to the tumor tissue sample collection and the interpretation of the clinical decision support report, our teams are at hand to assist you every step of the way. You can request support at any time. Should you need assistance on how to order a biomarker test, how to prepare the cancer tissue and ship the specimen, or how to read the final report on OncoSHARE, we are here to help!